Clinical Trial Update: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the renal hemodynamic effects of RLX030A in subjects with chronic heart failure has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• RLX030A

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure (CHF) | Phase 2 | Status: COMPLETED